Skip to main content
Back to timeline
BiotechnologySource publication:

Harbour BioMed's LET003 IND Accepted in China: First Antibody Designed With the Hu-mAtrIx AI Platform Reaches Regulatory Filing for Overweight and Obesity

Synopsis

Harbour BioMed said China's National Medical Products Administration has accepted its IND application for LET003, a monoclonal antibody targeting ACVR2A/2B for overweight or obesity, and the company's first candidate developed with its Hu-mAtrIx AI platform. The company reports that in preclinical studies LET003 showed pharmacokinetics superior to several competitor molecules and, combined with semaglutide, enhanced fat reduction while preserving lean mass. Acceptance starts regulatory review only; LET003 has not entered clinical testing, and its safety and efficacy in people remain to be assessed.

AI-generated editorial illustration: Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity

Interpretation

LET003, the first Harbour BioMed candidate developed with the Hu-mAtrIx AI platform, has had its IND application for overweight or obesity accepted by China's National Medical Products Administration, a first regulatory step toward clinical development. Until now LET003 had only preclinical data and no human study; acceptance moves the antibody into regulatory review, but dosing has not begun. Harbour BioMed announced the acceptance, with statements from founder, chairman and CEO Dr. Jingsong Wang and Bob Zhang, president of the metabolic disease franchise, placing LET003 within its obesity portfolio.

LET003 is designed as a monoclonal antibody that blocks both ACVR2A and ACVR2B, activin receptors that help regulate the balance between muscle and fat metabolism. Existing GLP-1-based weight-loss therapies produce substantial weight loss, but the accompanying loss of lean mass is a major challenge for optimizing body composition and long-term outcomes. The company reports that in preclinical animal models LET003 combined with semaglutide enhanced fat reduction while effectively preserving lean mass, and at a lower dose achieved lean-mass-promoting effects comparable to bimagrumab at a higher dose.

Perspective

The demonstrated scope is limited to regulatory acceptance and preclinical data: the NMPA accepted the IND application for LET003, and the company reports pharmacokinetics superior to several competitor molecules in preclinical studies and, in animal models, enhanced fat reduction with lean mass preservation when combined with semaglutide. It suits readers following AI-assisted antibody discovery and investigational obesity therapies.

Acceptance is not approval to run trials, and it does not show that LET003 is effective or safe in people; the pharmacokinetic advantage and the fat-reduction and lean-mass effects all come from preclinical studies, and the company's "potential best-in-class" description is its own assessment pending clinical development.